Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2013
CC-292 is an oral agent that is under clinical development for the treatment of rheumatoid arthritis an autoimmune inflammatory disorder. This study will test the clinical effectiveness and safety of an orally (PO) administered dose of CC-292 compared to placebo in US female patients currently on background Methotrexate (MTX) with active Rheumatoid Arthritis (RA
Epistemonikos ID: 8b9aaa197052aff080cb5ce734a359e4ef4454fd
First added on: Mar 23, 2022